ALK and non-small cell lung carcinoma: The activity of lorlatinib was confirmed in a large, randomized, phase 3 study B7461006 (CROWN; NCT03052608) testing lorlatinib versus crizotinib in patients with previously untreated ALK-positive advanced NSCLC.